MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2– advanced breast cancer: the multinational randomized phase III studyQing Yuan Zhang, Xi Hu, Yong Yin et al.|Therapeutic Advances in Medical Oncology|2020Cited by 110
Comparison of therapeutic evaluation between WHO criteria and RECIST for advanced breast cancerLing Leng, Zhong Sheng Tong|Zhonghua zhongliu fangzhi zazhi|2008Cited by 0